Cargando…

The Efficacy and Safety of Linezolid and Glycopeptides in the Treatment of Staphylococcus aureus Infections

To assess the effectiveness and safety of linezolid in comparison with glycopeptides (vancomycin and teicoplanin) for the treatment of Staphylococcus aureus infections, we conducted a meta-analysis of relevant randomized controlled trials. A thorough search of Pubmed and other databases was performe...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Jinjian, Ye, Xiaohua, Chen, Cha, Chen, Sidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590119/
https://www.ncbi.nlm.nih.gov/pubmed/23484002
http://dx.doi.org/10.1371/journal.pone.0058240
_version_ 1782261808832184320
author Fu, Jinjian
Ye, Xiaohua
Chen, Cha
Chen, Sidong
author_facet Fu, Jinjian
Ye, Xiaohua
Chen, Cha
Chen, Sidong
author_sort Fu, Jinjian
collection PubMed
description To assess the effectiveness and safety of linezolid in comparison with glycopeptides (vancomycin and teicoplanin) for the treatment of Staphylococcus aureus infections, we conducted a meta-analysis of relevant randomized controlled trials. A thorough search of Pubmed and other databases was performed. Thirteen trials on 3863 clinically assessed patients were included. Linezolid was slightly more effective than glycopeptides in the intent-to-treat population (odds ratio [OR], 1.05; 95% confidence interval [CI], 1.01–1.10), was more effective in clinically assessed patients (OR 95% CI: 1.38, 1.17–1.64) and in all microbiologically assessed patients (OR 95% CI: 1.38, 1.15–1.65). Linezolid was associated with better treatment in skin and soft-tissue infections (SSTIs) patients (OR 95% CI: 1.61, 1.22–2.12), but not in bacteraemia (OR 95% CI: 1.24, 0.78–1.97) or pneumonia (OR 95% CI: 1.25, 0.97–1.60) patients. No difference of mortality between linezolid and glycopeptides was seen in the pooled trials (OR 95% CI: 0.98, 0.83–1.15). While linezolid was associated with more haematological (OR 95% CI: 2.23, 1.07–4.65) and gastrointestinal events (OR 95% CI: 2.34, 1.53–3.59), a significantly fewer events of skin adverse effects (OR 95% CI: 0.27, 0.16–0.46) and nephrotoxicity (OR 95% CI: 0.45, 0.28–0.72) were recorded in linezolid. Based on the analysis of the pooled data of randomized control trials, linezolid should be a better choice for treatment of patients with S. aureus infections, especially in SSTIs patients than glycopeptides. However, when physicians choose to use linezolid, risk of haematological and gastrointestinal events should be taken into account according to the characteristics of the specific patient populations.
format Online
Article
Text
id pubmed-3590119
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-35901192013-03-12 The Efficacy and Safety of Linezolid and Glycopeptides in the Treatment of Staphylococcus aureus Infections Fu, Jinjian Ye, Xiaohua Chen, Cha Chen, Sidong PLoS One Research Article To assess the effectiveness and safety of linezolid in comparison with glycopeptides (vancomycin and teicoplanin) for the treatment of Staphylococcus aureus infections, we conducted a meta-analysis of relevant randomized controlled trials. A thorough search of Pubmed and other databases was performed. Thirteen trials on 3863 clinically assessed patients were included. Linezolid was slightly more effective than glycopeptides in the intent-to-treat population (odds ratio [OR], 1.05; 95% confidence interval [CI], 1.01–1.10), was more effective in clinically assessed patients (OR 95% CI: 1.38, 1.17–1.64) and in all microbiologically assessed patients (OR 95% CI: 1.38, 1.15–1.65). Linezolid was associated with better treatment in skin and soft-tissue infections (SSTIs) patients (OR 95% CI: 1.61, 1.22–2.12), but not in bacteraemia (OR 95% CI: 1.24, 0.78–1.97) or pneumonia (OR 95% CI: 1.25, 0.97–1.60) patients. No difference of mortality between linezolid and glycopeptides was seen in the pooled trials (OR 95% CI: 0.98, 0.83–1.15). While linezolid was associated with more haematological (OR 95% CI: 2.23, 1.07–4.65) and gastrointestinal events (OR 95% CI: 2.34, 1.53–3.59), a significantly fewer events of skin adverse effects (OR 95% CI: 0.27, 0.16–0.46) and nephrotoxicity (OR 95% CI: 0.45, 0.28–0.72) were recorded in linezolid. Based on the analysis of the pooled data of randomized control trials, linezolid should be a better choice for treatment of patients with S. aureus infections, especially in SSTIs patients than glycopeptides. However, when physicians choose to use linezolid, risk of haematological and gastrointestinal events should be taken into account according to the characteristics of the specific patient populations. Public Library of Science 2013-03-06 /pmc/articles/PMC3590119/ /pubmed/23484002 http://dx.doi.org/10.1371/journal.pone.0058240 Text en © 2013 Fu et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Fu, Jinjian
Ye, Xiaohua
Chen, Cha
Chen, Sidong
The Efficacy and Safety of Linezolid and Glycopeptides in the Treatment of Staphylococcus aureus Infections
title The Efficacy and Safety of Linezolid and Glycopeptides in the Treatment of Staphylococcus aureus Infections
title_full The Efficacy and Safety of Linezolid and Glycopeptides in the Treatment of Staphylococcus aureus Infections
title_fullStr The Efficacy and Safety of Linezolid and Glycopeptides in the Treatment of Staphylococcus aureus Infections
title_full_unstemmed The Efficacy and Safety of Linezolid and Glycopeptides in the Treatment of Staphylococcus aureus Infections
title_short The Efficacy and Safety of Linezolid and Glycopeptides in the Treatment of Staphylococcus aureus Infections
title_sort efficacy and safety of linezolid and glycopeptides in the treatment of staphylococcus aureus infections
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590119/
https://www.ncbi.nlm.nih.gov/pubmed/23484002
http://dx.doi.org/10.1371/journal.pone.0058240
work_keys_str_mv AT fujinjian theefficacyandsafetyoflinezolidandglycopeptidesinthetreatmentofstaphylococcusaureusinfections
AT yexiaohua theefficacyandsafetyoflinezolidandglycopeptidesinthetreatmentofstaphylococcusaureusinfections
AT chencha theefficacyandsafetyoflinezolidandglycopeptidesinthetreatmentofstaphylococcusaureusinfections
AT chensidong theefficacyandsafetyoflinezolidandglycopeptidesinthetreatmentofstaphylococcusaureusinfections
AT fujinjian efficacyandsafetyoflinezolidandglycopeptidesinthetreatmentofstaphylococcusaureusinfections
AT yexiaohua efficacyandsafetyoflinezolidandglycopeptidesinthetreatmentofstaphylococcusaureusinfections
AT chencha efficacyandsafetyoflinezolidandglycopeptidesinthetreatmentofstaphylococcusaureusinfections
AT chensidong efficacyandsafetyoflinezolidandglycopeptidesinthetreatmentofstaphylococcusaureusinfections